AI could uncover silent heart failure in diabetes patients

NCT ID NCT06593314

Recruiting now Knowledge-focused Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an AI tool called EchoGo can help doctors spot early signs of heart failure in people with type 2 diabetes who have no symptoms. Researchers will send alerts to doctors about patients at risk, and see if this leads to more prescriptions of heart-protecting medications. The trial involves 800 participants and their healthcare providers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI algorithm (EchoGo) and clinical decision support alerts
What this could lead to: If successful, this could help doctors identify hidden heart failure in diabetes patients earlier and start medications to prevent it from worsening.
What could go wrong: This is a pragmatic trial testing a decision-support tool, not a new drug. The AI may not change prescribing habits, and benefits depend on real-world adoption.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus diastolic heart failure prevention target heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES HEART FAILURE

Contacts and locations

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.